Schering Claritin-D 24-hour swallowing difficulty addressed anew in July 23 "Dear Doctor" letter.
Executive Summary
SCHERING CLARITIN-D 12-HOUR MAY BE USED IN PATIENTS WITH SWALLOWING DIFFICULTY who should not receive the 24-hour version of the loratadine/pseudoephedrine product, the company says in a July 23 "Dear Doctor" letter to prescribers. "For these patients, you may want to consider prescribing Claritin-D 12-hour (5 mg loratadine/120 mg pseudoephedrine sulfate, USP) extended-release tablets instead of Claritin-D 24-hour," the letter states.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth